scispace - formally typeset
C

Cédric Cleyrat

Researcher at University of New Mexico

Publications -  27
Citations -  5668

Cédric Cleyrat is an academic researcher from University of New Mexico. The author has contributed to research in topics: Syk & Calreticulin. The author has an hindex of 11, co-authored 26 publications receiving 5160 citations. Previous affiliations of Cédric Cleyrat include University of Nantes & French Institute of Health and Medical Research.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal Article

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2459 more
- 01 Jan 2016 - 
Journal ArticleDOI

Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

Daniel J. Klionsky, +2522 more
- 01 Jan 2016 - 
TL;DR: Author(s): Klionsky, DJ; Abdelmohsen, K; Abe, A; Abedin, MJ; Abeliovich, H; A Frozena, AA; Adachi, H, Adeli, K, Adhihetty, PJ; Adler, SG; Agam, G; Agarwal, R; Aghi, MK; Agnello, M; Agostinis, P; Aguilar, PV; Aguirre-Ghis
Journal ArticleDOI

Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F

Marjorie Boissinot, +6 more
- 24 Feb 2011 - 
TL;DR: There is evidence that inflammation-linked cytokines are required for the growth of JAK2V617F-mutated erythroid progenitors in Polycythemia vera, and blocking the c-MET/HGF/IL-11 pathways could be of interest as an additional therapeutic option in PV.
Journal ArticleDOI

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.

François Girodon, +8 more
- 01 Nov 2008 - 
TL;DR: Hydroxyurea therapy reduced the percentage of JAK2V617F mutant alleles by >30% in 13/25 patients with essential thrombocythemia or polycythemia vera within the first year after diagnosis, and Prospective studies are needed to determine the prognostic value of reduced JAK1 V617F allele burden under cytoreductive therapy.